دورية أكاديمية

Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis.

التفاصيل البيبلوغرافية
العنوان: Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis.
المؤلفون: Ou, Sai‐Hong Ignatius, Sommers, Karen R., Azada, Michele C., Garon, Edward B.
المصدر: Oncologist; Feb2015, Vol. 20 Issue 2, p224-226, 5p
مصطلحات موضوعية: ARTICULATION disorders, COMPUTED tomography, IMMUNOHISTOCHEMISTRY, LUNG cancer, MAGNETIC resonance imaging, LUMBAR puncture, MENINGEAL cancer, STEROIDS, TACTILE agnosia, PARESTHESIA, PROTEIN kinase inhibitors, DIAGNOSIS
مستخلص: This report describes a patient with ALK‐rearranged non‐small cell lung cancer who developed diffuse leptomeningeal carcinomatosis as the only “site” of progression after a prolonged response to crizotinib and who has been treated successfully with a second‐generation ALK inhibitor alone for >15 months. [ABSTRACT FROM AUTHOR]
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10837159
DOI:10.1634/theoncologist.2014-0309